Tag: IBD-
Risk for Adverse Events Not Increased After COVID-19 Vaccine in IBD
Frequency of adverse events was higher for those younger than 50 years, individuals with prior COVID-19 history
Infliximab May Reduce Immunogenicity to SARS-CoV-2 Vaccine
Antibody concentrations lower in infliximab-treated individuals with IBD receiving single dose of BNT162b2 or ChAdOx1 nCoV-19 vaccine
2001 to 2018 Saw Increase in Estimated Prevalence of IBD in Seniors
Increase higher among non-Hispanic Blacks, while prevalence was consistently highest for non-Hispanic Whites
Response to COVID-19 Vaccine Positive in Patients With IBD
Antibody response in IBD patients, including those receiving biologic therapy at the time of vaccination, similar to that of controls without IBD
Prevalence of Migraine, Severe Headache Up for Adults With IBD
Correlation of migraine or severe headache with IBD remains significant overall after adjustment for all covariates
Exposure to Greenspace Linked to Lower Risk for Pediatric-Onset IBD
Risk reduced for both ulcerative colitis, Crohn disease; linear dose response seen across increasing quartiles of greenspace
Cigarette Smoke Adds to Colorectal Neoplasia Risk in Patients With IBD
Adding smoke exposure improves the current risk stratification for colorectal neoplasia surveillance strategies
Use of Health Services Up for Adults With Inflammatory Bowel Disease
IBD associated with increased prevalence of being prescribed medication and having received acute care services
Crohn Disease, Comorbidities Up Risk for Severe Pneumococcal Disease
Receipt of PCV13 alone or in combination with PPSV23 predicts fivefold reduced risk for SPD compared with no vaccination
Polygenic Risk Scores May Improve IBD Risk Prediction
For every population in BioMe biobank, combining risk scores from distinct ancestral populations improved risk prediction for IBD
